Communiqués AC Immune SA

Actions

ACIU

CH0329023102

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
2,660 ^USD	-6,01%		-0,75%	-15,29%

24/09	Wall Street titube sous l'effet du cocktail taux-pétrole
24/09	Prises de bénéfices sur AC Immune, malgré l'enthousiasme de Jefferies

Communiqués

24/09	AC Immune Reports Positive Safety and Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104	AQ
23/09	AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104	AQ
20/08	AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764	AQ
11/08	AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)	AQ
05/08	AC Immune: Q2 Earnings Snapshot	AQ
05/08	AC Immune First Half 2026 Financial and Corporate Update	AQ
07/07	AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026	AQ
30/06	AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease	AQ
11/06	AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease	AQ
22/05	AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS	AQ
12/05	AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM	AQ
30/04	AC Immune: Q1 Earnings Snapshot	AQ
30/04	AC Immune First Quarter 2026 Financial and Corporate Updates	AQ
30/04	AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease	AQ
07/04	AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly	AQ
19/03	AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026	AQ
13/03	AC Immune: Q4 Earnings Snapshot	AQ
13/03	AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update	AQ
06/03	AC Immune Announces Upcoming Industry Symposium on Parkinson's disease and Presentation at AD/PD 2026	AQ
05/03	AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026	AQ
24/02	AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor	AQ
11/12	AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease	AQ
11/11	AC Immune to Present at the Jefferies 2025 London Healthcare Conference	AQ
04/11	AC Immune: Q3 Earnings Snapshot	AQ
04/11	AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update	AQ